Article summary
In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its “new framework for psychedelic drugs”. The four agency staffers kick off the article by outlining the severity of the mental health crisis in the U.S., focusing on depression and PTSD in particular, before stating that FDA […]
Continue to the original publication for the complete article.